Osei Jessica Amankwah, Peña-Sánchez Juan Nicolás, Fowler Sharyle A, Muhajarine Nazeem, Kaplan Gilaad G, Lix Lisa M
Department of Community Health and Epidemiology, College of Medicine, University Saskatchewan, Saskatoon, Saskatchewan, Canada.
Department of Medicine, College of Medicine, University Saskatchewan, Saskatoon, Saskatchewan, Canada.
J Can Assoc Gastroenterol. 2021 Mar 16;4(6):296-305. doi: 10.1093/jcag/gwab003. eCollection 2021 Dec.
Our study aimed to calculate the prevalence and estimate the direct health care costs of inflammatory bowel disease (IBD), and test if trends in the prevalence and direct health care costs of IBD increased over two decades in the province of Saskatchewan, Canada.
We conducted a retrospective population-based cohort study using administrative health data of Saskatchewan between 1999/2000 and 2016/2017 fiscal years. A validated case definition was used to identify prevalent IBD cases. Direct health care costs were estimated in 2013/2014 Canadian dollars. Generalized linear models with generalized estimating equations tested the trend. Annual prevalence rates and direct health care costs were estimated along with their 95% confidence intervals (95%CI).
In 2016/2017, 6468 IBD cases were observed in our cohort; Crohn's disease: 3663 (56.6%), ulcerative colitis: 2805 (43.4%). The prevalence of IBD increased from 341/100,000 (95%CI 340 to 341) in 1999/2000 to 664/100,000 (95%CI 663 to 665) population in 2016/2017, resulting in a 3.3% (95%CI 2.4 to 4.3) average annual increase. The estimated average health care cost for each IBD patient increased from $1879 (95%CI 1686 to 2093) in 1999/2000 to $7185 (95%CI 6733 to 7668) in 2016/2017, corresponding to an average annual increase of 9.5% (95%CI 8.9 to 10.1).
Our results provide relevant information and analysis on the burden of IBD in Saskatchewan. The evidence of the constant increasing prevalence and health care cost trends of IBD needs to be recognized by health care decision-makers to promote cost-effective health care policies at provincial and national levels and respond to the needs of patients living with IBD.
我们的研究旨在计算炎症性肠病(IBD)的患病率并估算其直接医疗费用,并检验加拿大萨斯喀彻温省IBD的患病率和直接医疗费用在二十年间是否呈上升趋势。
我们利用1999/2000至2016/2017财政年度萨斯喀彻温省的行政卫生数据进行了一项基于人群的回顾性队列研究。采用经过验证的病例定义来识别IBD现患病例。直接医疗费用以2013/2014年加拿大元估算。使用广义估计方程的广义线性模型检验趋势。估算了年患病率和直接医疗费用及其95%置信区间(95%CI)。
在2016/2017年,我们的队列中观察到6468例IBD病例;克罗恩病:3663例(56.6%),溃疡性结肠炎:2805例(43.4%)。IBD的患病率从1999/2000年的341/10万(95%CI 340至341)增至2016/2017年的664/10万(95%CI 663至665),年均增长3.3%(95%CI 2.4至4.3)。每位IBD患者的估计平均医疗费用从1999/2000年的1879加元(95%CI 1686至2093)增至2016/2017年的7185加元(95%CI 6733至7668),年均增长9.5%(95%CI 8.9至10.1)。
我们的结果提供了有关萨斯喀彻温省IBD负担的相关信息和分析。IBD患病率和医疗费用持续上升趋势的证据需要医疗决策者认识到,以促进省级和国家级具有成本效益的医疗政策,并满足IBD患者的需求。